CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer-Treated with Neoadjuvant Systemic Therapy.
Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer-Treated with Neoadjuvant Systemic Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
炎性乳腺癌(IBC)是一种罕见(1%-5%)且具有侵袭性的乳腺癌类型,约占乳腺癌死亡病例的10%。在局部期,标准治疗为新辅助化疗(NACT)±抗HER2治疗,随后行手术。本研究探讨了临床病理变量、间质TIL(肿瘤浸润淋巴细胞)(sTIL)与病理完全缓解(pCR)之间的关联,以及pCR的预后价值。我们纳入了1996年10月至2021年10月在八家欧洲医院接受NACT治疗的494例局部期IBC患者。收集标准临床病理变量并进行中心病理学审查,包括sTIL评估。采用Firth logistic回归模型评估相关性。采用Cox回归评估pCR和残余癌负荷(RCB)对无病生存期(DFS)、无远处复发生存期(DRFS)和总生存期(OS)的作用。按受体状态分布如下:雌激素受体阴性(ER-)/HER2-占26.4%;ER-/HER2+占22.0%;ER+/HER2-占37.4%;ER+/HER2+占14.1%。总体pCR率为26.3%,在HER2+组中最高(ER-/HER2+组为45.9%,ER+/HER2+组为42.9%)。sTIL水平较低(中位数:5.3%),在ER-/HER2-组中最高(中位数:10%)。高肿瘤分级、ER阴性、HER2阳性、较高的sTIL水平以及基于紫杉烷类的NACT与pCR显著相关。多变量分析显示,pCR与DFS、DRFS和OS的改善相关。在未达到pCR的患者中,RCB评分与生存期独立相关。总之,IBC中sTIL水平较低,但可预测pCR。pCR和RCB在接受NACT治疗的IBC中均具有独立的预后作用。意义:IBC是一种罕见但极具侵袭性的乳腺癌类型。系统治疗后的pCR的预后作用以及sTILs对pCR的预测价值在一般乳腺癌人群中已得到充分证实;然而,在IBC中仅有有限的信息可用。我们汇集了迄今为止最大的回顾性IBC系列,并证明sTIL可预测pCR。我们强调,在IBC中达到pCR仍然至关重要。
UNLABELLED: Inflammatory breast cancer (IBC) is a rare (1%-5%), aggressive form of breast cancer, accounting for approximately 10% of breast cancer mortality. In the localized setting, standard of care is neoadjuvant chemotherapy (NACT) ± anti-HER2 therapy, followed by surgery.
Here we investigated associations between clinicopathologic variables, stromal tumor-infiltrating lymphocytes (sTIL), and pathologic complete response (pCR), and the prognostic value of pCR.
We included 494 localized patients with IBC treated with NACT from October 1996 to October 2021 in eight European hospitals. Standard clinicopathologic variables were collected and central pathologic review was performed, including sTIL. Associations were assessed using Firth logistic regression models.
Cox regressions were used to evaluate the role of pCR and residual cancer burden (RCB) on disease-free survival (DFS), distant recurrence-free survival (DRFS), and overall survival (OS). Distribution according to receptor status was as follows: 26. 4% estrogen receptor negative (ER-)/HER2-; 22. 0% ER-/HER2+; 37. 4% ER+/HER2-, and 14. 1% ER+/HER2+.
Overall pCR rate was 26. 3%, being highest in the HER2+ groups (45. 9% for ER-/HER2+ and 42. 9% for ER+/HER2+). sTILs were low (median: 5. 3%), being highest in the ER-/HER2- group (median: 10%). High tumor grade, ER negativity, HER2 positivity, higher sTILs, and taxane-based NACT were significantly associated with pCR. pCR was associated with improved DFS, DRFS, and OS in multivariable analyses. RCB score in patients not achieving pCR was independently associated with survival.
In conclusion, sTILs were low in IBC, but were predictive of pCR. Both pCR and RCB have an independent prognostic role in IBC treated with NACT. SIGNIFICANCE: IBC is a rare, but very aggressive type of breast cancer. The prognostic role of pCR after systemic therapy and the predictive value of sTILs for pCR are well established in the general breast cancer population; however, only limited information is available in IBC.
We assembled the largest retrospective IBC series so far and demonstrated that sTIL is predictive of pCR.
We emphasize that reaching pCR remains of utmost importance in IBC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。